Document:

exv10w14w2

EXHIBIT 10.14.2

AMENDMENT TO THE

DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT

BETWEEN

WYETH, ACTING THROUGH ITS WYETH CONSUMER HEALTHCARE DIVISION,

AND

IMPAX LABORATORIES, INC.

This Amendment, effective as of February 14, 2005 (the “Effective Date”), to the Development,
License and Supply Agreement, dated as of June 1, 2002 and amended by letters dated November 19,
2002, April 23, 2003 and May 15, 2003 and amendment dated July 9, 2004, for
Loratadine/Pseudoephedrine Combination Tablets (the “Agreement”) is entered into by and between
Wyeth, acting through its Wyeth Consumer Healthcare Division (hereinafter called “WCH”), and Impax
Laboratories, Inc. (hereinafter called “IMPAX”).

PURPOSE

WHEREAS, under the Agreement, IMPAX has agreed to supply WCH with D-24 Product (as defined in the
Agreement);

WHEREAS, IMPAX and WCH wish to terminate the Agreement with respect to the D-24 Product only, all
in accordance with the terms and subject to the conditions set forth in this Amendment.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained
herein and intending to be legally bound hereby, the parties hereby agree as follows:

1. Unless otherwise expressly defined herein, all capitalized terms used herein shall have the same
meaning as defined in the Agreement.

2. The Parties hereby agree that as of the Effective Date the Agreement shall be terminated with
respect to the D-24 Product only. All references to the D-24 Product and any provisions of the
Agreement which relate solely to the D-24 Product shall be deemed removed from the Agreement. Such
termination shall not give rise to the payment of any penalty, damages or indemnification by either
Party to the other Party and WCH shall have no further rights or obligations with respect to the
D-24 Product, including, without limitation, any right or license to use any of IMPAX Confidential
Information with respect to the D-24 Product. In full satisfaction of any and all obligations
(past, present or future) that WCH has or may have with respect to the D-24 Product under the
Agreement or otherwise, WCH agrees to pay IMPAX within thirty (30) days after the Effective Date,
and IMPAX agrees to accept, the sum of Three Hundred Thousand Dollars ($300,000). In consideration
of IMPAX executing this Amendment and agreeing to the terms herein, WCH agrees that IMPAX does not
have any further

 

 

obligations to WCH (past, present or future) with respect to the D-24 Product under the Agreement.
Nothing contained herein shall relieve either Party from its obligations to maintain
confidentiality under the Agreement.

3. All other terms and conditions of the Agreement are hereby confirmed and shall remain in full
force and effect. In the event of any conflict with the provisions of this Amendment and any of the
provisions of the Agreement, the provisions of this Amendment shall control.

IN WITNESS WHEREOF, the undersigned have executed this Amendment.

WYETH, acting through its Wyeth Consumer Healthcare Division

	 	 	 	 	 
	 	 	 
	 	By:  	/s/ Illegible
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

	 	 	 	 	 
	 	 	IMPAX LABORATORIES, INC.

 	 
	 	By:  	/s/ David S. Doll
 	 
	 	 	Name:  	David S. Doll 	 
	 	 	Title:  	Sr. Vice President,
Sales and Marketing 	 

-2-exv10w15

EXHIBIT 10.15

     XXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

LICENSING, CONTRACT MANUFACTURING & SUPPLY AGREEMENT

between

SCHERING CORPORATION

and

IMPAX LABORATORIES, INC.

 

 

LICENSING, CONTRACT MANUFACTURING & SUPPLY AGREEMENT

     THIS AGREEMENT, effective as of the last date of signature appearing below (the “Effective
Date”), is entered into by and between Schering Corporation, a corporation organized under the laws
of New Jersey, with its principal office at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033
(hereafter called “Schering”), and Impax Laboratories, Inc., a corporation organized under the laws
of Delaware, with its principal offices at 30831 Huntwood Avenue, Hayward, California 94550
(hereafter called “Impax”).

PURPOSE

     WHEREAS, Impax desires to manufacture and supply to Schering, and Schering desires to purchase
from Impax, Schering’s orders of the Product for sale in the Territory (as hereinafter defined).

     NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained and intending to be legally bound hereby, the parties hereby agree as follows:

ARTICLE I

DEFINITIONS

     In this Agreement, and in the exhibits to this Agreement the following terms, whether used in
the singular or plural, shall have the respective meanings set forth below:

     1.1. The term “Active Pharmaceutical Ingredient” shall mean loratadine and/or pseudoephedrine
sulfate in bulk form conforming to the Active Pharmaceutical Ingredient Specifications.

     1.2. The term “Active Pharmaceutical Ingredient Specifications” shall mean the specifications
and quality control testing procedures for the Active Pharmaceutical Ingredient set forth in
Exhibit 1.2 hereto which conforms to the ANDA for the Product, as amended from time to time by the
mutual agreement of the parties hereto.

     1.3. The term “Affiliate” shall mean any individual or entity directly or indirectly
controlling, controlled by or under common control with, a party to this Agreement. For purposes
of this Agreement, the direct or indirect ownership of over fifty percent (50%) of the outstanding
voting securities of an entity, or the right to receive over fifty percent (50%) of the profits or
earnings of an entity shall be deemed to constitute control. Such other relationship as in fact
results in actual control over the management, business and affairs of an entity shall also be
deemed to constitute control.

     1.4. The term “Agreement” shall mean this agreement and any and all exhibits, appendices and
other addenda attached hereto, including as they may be modified from time to time in accordance
with the provisions of this Agreement.

 

 

     1.5. The term “Approved Facilities” shall mean that facilities of Impax located at Buildings
No. 1 and No. 2, 30831 Huntwood Avenue, Haywood, California 94545 and its facility located at 3735
Castor Avenue, Philadelphia, PA 19124 and referenced in the Health Registrations as an approved
site for the Manufacture of the Product, including without limitation all of the equipment,
machinery and facilities of Impax at such location that are used in the Manufacturing, testing,
stability oversight, and storage of Product.

     1.6. The term “ANDA” shall mean an abbreviated new drug application filed with the FDA seeking
approval to market and sell a generic prescription or OTC pharmaceutical product in the Territory
and any supplements and amendments, and any such approvals granted by the FDA based upon such
application.

     1.7. The term “CMC” shall mean the chemistry, manufacturing, and controls section(s) and data
in the Health Registrations that cover the chemical composition of the Product and its components
and the control and Manufacturing process for the Product, as amended or supplemented from time to
time.

     1.8. “Commercially Reasonable Efforts” means efforts and resources normally used by a party
for a compound or product owned by it or to which it has rights, which is of similar market
potential at a similar stage in its product life, taking into account the competitiveness of the
marketplace, the proprietary position of the compound or product, the regulatory structure
involved, the profitability of the applicable products, and other relevant factors. It is
anticipated that the level of efforts and resources may change at different times during the
product life cycle of a compound or product.

     1.9. The term “Cure Price” shall mean the out-of-pocket cost to Schering for the Product
Manufactured by Schering, an Affiliate of its or a Third Party, due to a Supply Failure, failure in
Product quality or other failure to comply with the Product Specifications, which Cure Price shall
not exceed 125% of the Price set forth on Exhibit 1.29.

     1.10. The term “FCA” shall mean Free Carrier as that term is used in Incoterms 2000 and as further
set forth in Section 5.2 hereof.

     1.11. The term “FDA” shall mean the United States Food and Drug Administration, or any successor
entity having jurisdiction over the transactions contemplated by this Agreement.

     1.12. The term “FDCA” shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§301-397, as
amended.

     1.13. The term “Force Majeure” shall mean any cause beyond the reasonable control of any
non-performing party, including without limitation, , strikes, lockouts, inability to procure labor
or material, fuels shortages, fires, explosions, earthquakes, riots, interference by civil or
military authorities, terrorism, outbreak of war or insurgence, acts of war (declared or
undeclared), sabotage, embargo, a national health emergency, or compliance with any order or
regulation of any government entity acting with color of right.

 

 

     1.14. The term “cGMPs” shall mean current good manufacturing practices for the methods to be used
in, and the facilities and controls to be used for, the manufacture, testing, stability oversight,
processing, packing and holding of drugs, as set forth in all applicable laws, rules and
regulations in the Territory or as may otherwise be established by the FDA, including all
amendments and supplements thereto, during the term of this Agreement.

     1.15. The term “Health Registrations” shall mean the technical, medical and scientific licenses,
registrations, authorizations and/or approvals of the Product (including the prerequisite
manufacturing approvals or authorizations, marketing authorization based upon such approvals and
pricing, Third Party reimbursement and labeling approvals related thereto) that are required by any
national, regional, state or local regulatory agency, department, bureau or other governmental
entity in the Territory, for the Manufacture, distribution, use or sale of Product in the
Territory, as amended or supplemented from time to time, including, without limitation, an ANDA or
NDA, for the Product, as amended or supplemented from time to time.

     1.16. The term “Impax Know-How” shall mean the formulation for the Product, Impax’s technology
related to slow release and/or sustained release tablet dosage forms, Impax’s ANDA for the Product
(including the CMC portions thereof), and all other data, information, instructions, processes,
procedures, assays and methods related to the Manufacture and/or testing of the Product which are
owned or controlled by Impax as of the Effective Date.

     1.17. The term “Initial Term” shall mean the period of time beginning on the Effective Date and
ending three (3) years after the date of the first purchase of Product by Schering from Impax for
sale in the Territory following receipt of Health Registration for the Product in the Territory.

     1.18. The term “Intellectual Property” shall mean any patents, patent applications, trademarks,
trademark applications, trade names, copyrights, trade secret rights, technology and all other
intellectual property rights owned or controlled by a party that are related to the Product or the
Manufacture or use thereof. With respect to Impax, Intellectual Property shall include, without
limitation, the Impax Know-How and Impax’s rights to any Inventions.

     1.19. The term “Inventions” shall mean any inventions, discoveries, or innovations, whether
patentable or not, relating to or arising out of the use of the Impax Know-How in connection with
the development and/or Manufacture of the Product by Impax.

     1.20. The term “Laws” shall mean all applicable federal, state or local statutes or laws, as well
as all rules and regulations promulgated thereunder, by any Regulatory Authorities in the
Territory, unless context requires otherwise. Any reference to a particular law or regulation will
be interpreted to include any revision of or successor to such statute, law, rule or regulation
regardless of how it is numbered or classified.

     1.21. The term “Loss” shall mean claims, liabilities, costs, damages, losses, judgments for
damages, or expenses (including reasonable attorneys’ fees).

 

 

     1.22. The term “Manufacture” “Manufactured” or “Manufacturing” shall mean all activities involved
in the manufacture, packaging, handling, storage and testing of the Product in accordance with and
pursuant to the terms of this Agreement.

     1.23. The term “NDA” shall mean a new drug application filed with the FDA seeking approval to
market and sell a new prescription or OTC pharmaceutical product in the Territory, and any such
approvals granted by the FDA based upon such application.

     1.24 The term “Orders” shall mean all quantities of the Product that shall be ordered by Schering
for the Territory for research and development (including without limitation clinical trial
materials), and for distribution, marketing (including samples), and sale of the Product in the
Territory.

     1.25. The term “Packaging Components” shall mean all materials and components used or incorporated
in the final (primary and secondary) packaging of the Product for distribution and sale in the
Territory.

     1.26. The term “Product” shall mean a product containing the Active Pharmaceutical Ingredients in
a twelve hour extended release tablet which is Manufactured in accordance with this Agreement and
conforming to the Product Specifications as marketed as a product not requiring a prescription by a
medical doctor or other health professional by Schering in the Territory.

     1.27. The term “Product Specifications” shall mean the specifications and quality control testing
procedures for the Product and as more fully set forth in Exhibit 1.27 hereto, as amended from time
to time in accordance with the terms of this Agreement and consistent with the ANDA covering the
Product.

     1.28. The term “Proprietary Information” shall mean any scientific, technical, clinical,
regulatory, marketing, financial or commercial information or data relating to the Product or the
Manufacture or use thereof, that is disclosed by one Party to the other Party pursuant to this
Agreement, or that is developed by a Party in the performance of its obligations under this
Agreement.

     1.29. The term “Price” shall mean the price as set forth on Exhibit 1.29 hereto for the Initial
Term. After the Initial Term, the Price shall be determined as set forth in Section 6.1 hereof.

     1.30. The term “Raw Materials” shall mean all raw materials, components, excipients, and Packaging
Components, other than Active Pharmaceutical Ingredient, useful or necessary for the Manufacture of
Product in accordance with this Agreement.

     1.31. The term “Regulatory Authority” shall mean the applicable government regulatory authority in
the Territory involved in granting the Health Registrations for the Product.

 

 

     1.32. The term “Supply Failure” shall mean Impax’s inability on more than two occasions during the
Initial Term or on more than two occasions during any renewal period of this Agreement or any
period subsequent to such failures to Manufacture enough Product pursuant to the forecasts referred
to in Section 3.3 to deliver no later than the delivery date set forth in the purchase order at
least seventy-five percent (75%) of the Product ordered by Schering for one calendar month.

     1.33. The term “Territory” shall mean the United States, and its commonwealths, territories and
possessions.

     1.34. The term “Third Party” shall mean any individual, corporation, trust, association, estate,
partnership, joint venture, limited liability company, governmental entity or other legal entity
other than Impax, Schering or their respective Affiliates.

ARTICLE II

LICENSE FEE

     2.1 License Fee. (a) In consideration of the initial fee and milestone payment set
forth in this Section 2.1, Impax grants to Schering a non-exclusive license under Impax’s ANDA,
know-how and other intellectual property as they relate to the Product and the other rights granted
to Schering under this Agreement including, but not limited to the rights to obtain supply of,
market and distribute the Product, for the Initial Term and any renewal term of this Agreement.

          (b)Within ten (10) business days of execution of this Agreement, Schering shall make an
initial payment of Two Million Two Hundred Fifty Thousand Dollars ($2,250,000); provided, however,
in the event that Impax does not receive tentative ANDA approval for the Product by January 1,
2003, Impax shall immediately reimburse Schering such initial fee. As soon as commercially
reasonable after receipt of tentative ANDA approval, Impax shall purchase, install and qualify
additional manufacturing machinery at a cost of at least One Million Five Hundred Thousand Dollars
($1,500,000) for the purpose of increasing its capacity to produce the Product in accordance with
its ANDA, as set forth on Exhibit 2.1(b).

          (c) Impax shall invoice Schering for its additional license payment of Two Million Two Hundred
Fifty Thousand Dollars ($2,250,000) (the “Final License Payment”) and Schering shall pay such
amount with its payment of the initial invoice from Impax for the first commercial delivery of
Product to Schering in accordance with this Agreement; provided, however, if the Product is not
approved to be sold as Over-The Counter pharmaceutical product by the FDA (“OTC”) in the Territory
on or prior to January 1, 2003, Schering shall not be required to pay the Final License Payment
until such approval has been granted. In the event that the Product has not been approved to be
sold OTC by November 30, 2003, Schering shall have the right to terminate the Agreement, with no
further obligations from either party, provided, however, Schering must pay for any product
delivered pursuant to firm purchase orders issued in accordance with Section 3.4 hereof. In the
event that Impax has received final ANDA approval,

 

 

and Impax has fulfilled all of its obligations under the Agreement, but Schering has not
placed a firm purchase order for Product by December 15, 2003, Schering shall pay Impax the Final
License Payment on such date.

ARTICLE III

SUPPLY OF PRODUCT

     3.1 Supply of Product. Subject to the terms and conditions of this Agreement, Impax shall
Manufacture and supply to Schering, and Schering shall purchase from Impax, the Product in
accordance with Impax’s ANDA and in amounts to be determined by Schering in its sole discretion
(but no less than batch size quantities); provided that Schering shall be required to purchase a
minimum of XXXXX tablets of the Product during the twelve (12) month period beginning with the
first shipment of Product from Impax for commercial sale by Schering. Notwithstanding the other
provisions of this Section 3.1, Schering shall not be subject to such minimum purchase requirements
until Impax has received approval to sell its Product OTC. Schering shall prepay 75% of the
initial order; provided, however, that such order shall not exceed Schering’s initial three months’
forecast of supply of Product. Nothing herein shall be construed as restricting or limiting
Schering’s right to manufacture the Product at Schering’s or its Affiliate’s facilities for use
and/or sale in the Territory.

     3.2 Supply of Raw Materials. Impax shall be responsible for
procuring, at its own expense, the supply of all Raw Materials and Active Pharmaceutical Ingredient
necessary for the Manufacture of Product in accordance with this Agreement. However, Schering shall
have the right to supply or procure the supply of Active Pharmaceutical Ingredient at the fixed
price to Impax set forth in Exhibit 3.1.

     3.3 Good Faith Forecasts. Impax represents that it
can adequately supply Schering with Product in accordance with the preliminary non-binding forecast
as set forth in Exhibit 3.3. Although the forecast on Exhibit 3.3 does not obligate Schering to
make any purchases of Product, the parties acknowledge that it represents a good faith estimate of
possible orders by Schering for Product during the Initial Term and
any renewal term.
 Within thirty
(30) days after the Effective Date, Schering shall provide Impax with a written twelve (12) month
forecast estimating the amounts to be supplied by Impax under this Agreement, and the desired
delivery dates therefor. Impax shall be obligated to provide Product up to 125% of the most recent
forecast (and use Commercially Reasonable Efforts to provide Product in excess of 125% of the most
recent forecast), upon receipt of a Purchase Order for such amount, as described in Section 3.4.
Thereafter, on or before the first day of each month during the term hereof, Schering shall
provide Impax with an updated written rolling forecast estimating Schering’s purchases from Impax
and the desired delivery dates therefor, for the succeeding twelve (12) month period. Such rolling
forecasts shall include the forecast from the previously forecasted eleven (11) month period in
addition to a forecast for the new month added. Such estimates shall be prepared in good faith,
but shall not be binding on Schering, except that
Schering shall place purchase orders for at least the quantity of products specified in the first
three (3) months of each such rolling forecast. Schering shall not be responsible for any loss or
expense incurred by Impax arising from such forecasts, except for such three (3) months’ purchase
orders. The obligation to give estimates is acknowledged by the parties to be a material provision
of this

 

 

Agreement. Accordingly, if Schering fails to give Impax an estimate after notice by Impax
of such failure and Schering’s continuing failure to provide an estimate to Impax, Impax and
Schering shall discuss the reasons for Schering’s failure and Impax will not decline to supply if
Impax determines in its reasonable judgment that Schering has an adequate reason for its failure to
furnish the estimate.

     3.4 Purchase Orders. Schering shall issue to Impax firm purchase orders for each
delivery, not later than twelve (12)weeks prior to the forecasted delivery date. In the event that
Schering’s initial purchase order for Product exceeds XXXXX tablets, Schering shall issue to Impax
a firm purchase order not later than six (6) months prior to the forecasted delivery date.
Schering shall be obligated to purchase, and Impax shall be obligated to sell, such quantities of
the Product as are set forth in the purchase order, on the delivery schedule set forth therein with
packaging initially to be either in bulk or in bottles of 1000 tablets pursuant to the approved
ANDA for the Product. In the event that the terms of any such purchase order are not consistent
with this Agreement, the terms of this Agreement shall prevail in the event that the amount of the
purchase order exceeds 125% of the good faith forecast, then Impax shall make all Commercially
Reasonable Efforts to modify its production schedule so as to deliver such additional quantities of
Product to Schering as soon as practicable. Impax shall promptly confirm receipt of the purchase
order as well as the delivery dates contained in the purchase order by written acknowledgment.

     Notwithstanding the foregoing, Schering may change firm purchase order dock dates, only if
changed at least —four (4) weeks prior to the original firm purchase order dock date, but any
costs incurred by Impax as a result of such change shall be borne by Schering (subject to approval
of such costs by Schering, such approval not to be unreasonably withheld) . In addition, Impax
will consider requests for changes to firm purchase order dock dates with less than four (4) weeks
prior notice, but Impax is under no obligation to agree to such changes. Such dock date changes
shall in no way reduce Schering’s liability for such firm purchase orders. Also, Schering may
change the Product Specifications of the Product, provided, however, that such changes shall in no
way reduce Schering’s liability for such firm purchase order, and further provided, that Schering
shall be responsible for all costs associated with such change to the Product Specifications and,
provided further, that Impax may delay delivery of Products which are the subject of a change in
Product Specifications for such reasonable period of time to enable Impax to comply with the
changed Product Specifications.

     3.5 Stoppage Due to Good Cause. Upon Schering’s written notice, Impax shall stop a
scheduled production run of the Product, at no cost to Schering, provided that such request is
based upon good cause. Good cause is defined as Impax’s failure to comply, or its inability to
assure compliance with cGMPs, Health Registrations or any other applicable Regulatory Authority
requirements, rules or regulations. Exercise by Schering of its rights under this Section
4.4 shall not prejudice any other rights or remedies that Schering may have under this
Agreement or otherwise at law or equity.

     3.6 Stoppage At Schering’s Discretion. Upon
Schering’s discretion and upon written notice, Impax shall stop a scheduled production run of the
Product at no cost to Impax and Schering shall promptly reimburse Impax for any cost which Impax
incurs as a result of such stoppage of production (subject to approval of such costs by Schering,
such approval not to be unreasonably withheld).

 

 

     3.7 Alternative Supply. Impax agrees to fully cooperate with Schering, at Schering’s
request and expense, to establish a back-up facility for the manufacture of the Product at one of
Schering’s, its Affiliate’s or Third Party’s manufacturing sites. Upon such request, Impax shall
promptly initiate a complete technology transfer of the manufacturing process, procedures and
standards used by Impax to Manufacture the Product so as to enable the back-up facility to
manufacture the Product in accordance with the applicable Health Registrations for the Product.
Impax and Schering shall use diligent efforts to ensure that the technology transfer is completed
as soon as reasonably practicable. In the event that Schering decides to exercise its rights under
this Section 3.7 and no Supply Failure or any other uncured material breach by Impax has occurred,
Schering shall be obligated to pay Impax XXXXX per tablet of Product or tablet of Schering’s
existing proprietary D-12 formulation manufactured by or for Schering for sale in the Territory
during the Agreement; provided, however, Schering shall not be obligated to pay Impax for any
Schering proprietary D-12 formulation product manufactured by Schering prior to the first shipment
by Impax of Product to Schering for commercial sale in accordance
with the Agreement. 

     Any such
payments due under this Section 3.7 shall be paid to Impax within sixty (60) days of the close of
each calendar quarter within which the tablets were manufactured and shall be accompanied by a
statement detailing the number of tablets manufactured and the calculation of the payment owed to
Impax. Schering shall keep records in sufficient detail to enable Impax to verify the calculation
of the number of tablets of Product manufactured during each quarter. Impax has the right, at its
discretion and expense, but not more frequently than one (1) time per calendar year, to inspect,
during ordinary business hours of Schering, records as may be necessary to verify Schering’s
calculation of any payment due under this Section 3.7.

     3.8 Capacity. Upon receipt of the forecasts provided for in Section 3.3, Impax shall
confirm its ability to meet such demand with existing capacity. If Impax confirms that it is
unable to meet such Schering forecast, the parties agree to negotiate revised forecasts or add
capacity as set forth below. Impax further agrees that any funding for additional capacity to
support the manufacture of the Product in accordance with the Agreement shall be born solely by
Impax; provided, however, in the event that such forecasts require capacity in excess of existing
capacity and such forecasts exceed by more than 25% the forecasts shown on Exhibit 3.3, Schering
and Impax shall share equally in the documented costs to add such capacity.

ARTICLE IV

DEVELOPMENT ACTIVITIES

     4.1
Impax’s Obligation. 

          (a) Impax shall be responsible, at its expense, for all
development and regulatory activities performed by or on behalf of Impax in connection with the
preparation, filing and maintenance of the ANDA for the Product.

          (b) At Schering’s option and expense, but subject to Impax’s Manufacturing and Product
development capabilities and capacity, Impax shall perform all development and regulatory
activities agreed upon by the parties beyond those activities required by Section 4.1(a).

 

 

          (c) Impax shall use its Commercially Reasonable Efforts to accelerate its development,
Manufacturing and regulatory activities related to the Product to enable it to supply Product to
Schering for sale in the Territory as soon as is reasonably practicable.

          (d) Subject to Section 3.8 hereof, Impax shall also purchase the necessary equipment and take
all other necessary steps to enable it to supply Schering’s Orders for the Products.

          (e) Impax shall provide 300,000 tablets (in two deliveries of 150,000 tablets each) to be
manufactured for stability testing purposes for currently unsubmitted bulk drum and blister
packages; and Impax shall further provide stability testing services in support of
commercialization of the Product in such packages.

     4.2. Cost Reductions. The parties shall work together to develop cost reductions, but
the foregoing does not constitute a guarantee by Impax of any cost reductions. Both parties agree
that cost reductions may be possible by improvements in the technology for Manufacturing or by
negotiating with regulatory authorities to achieve cost effective product specifications or by
changes in regulatory standards applicable to manufacturing, among other reasons. Any such cost
reduction program shall be expressly agreed to in writing by Impax and Schering prior to
implementation and prior to any reduction in the price of the Product hereunder. In the event a
cost reduction program is accepted, both parties agree to a sharing plan based upon the following
conceptual guidelines:

          a) Any cost savings initiated by Schering related to independently negotiated material
pricing, formula change or packaging changes shall be to Schering’s sole benefit.

          b) Any cost savings resulting from process changes initiated by Impax shall be allocated 75%
to Impax and 25% to Schering.

          c) Any Raw Material cost savings resulting from joint sourcing strategies/synergies or by
Impax sourcing activities shall be negotiated and shared with no less than 50% of such savings
allocated to Schering.

ARTICLE V

DELIVERY AND RELATED MATTERS

     5.1 Certificate of Analysis. Impax shall provide Schering with each shipment of
Product a certificate from Impax’s quality assurance department that includes the results of
quality control testing in accordance with the Product Specifications and which indicates that the
Product contained in the shipment meets the Product Specifications. Impax shall also notify
Schering in writing of the specific storage conditions and any special handling procedures for the
Product.

     5.2 Risk of Loss. Delivery of each shipment of the Product shall be made FCA.
Impax shall arrange for transportation of the Product to a destination designated by Schering and
by a common carrier designated by Schering. Title to and risk of loss of the Product shall pass to
Schering at the time of delivery to the carrier. Impax shall promptly invoice Schering for all

 

 

Product shipped.

     5.3 Storage. Impax, at its own expense, shall maintain adequate and appropriately
segregated facilities in accordance with cGMPs and Health Registrations at the Approved Facilities
for storage of the Product pending delivery to the designated carrier pursuant to Section 5.2
hereof.

     5.4 Delay and Failure to Supply.

          (a) In the event that Impax shall have reason to believe that it will be unable to supply
Schering with the full quantity of the Product forecasted to be ordered or actually ordered by
Schering in a timely manner, Impax shall promptly (and in any event within five (5) business days)
notify Schering thereof. If Impax shall so notify Schering, or if Impax shall fail to provide
Schering with adequate assurances of timely performance upon Schering’s request therefor
(regardless of whether past performance has complied herewith or not), Schering and Impax shall
promptly meet to discuss how to thereafter supply Product in a timely manner. If, however,
Schering at any time determines in the exercise of its reasonable judgment that there will be a
Supply Failure or that there is a Supply Failure, Schering or an Affiliate of Schering may (but
shall not be obligated to) Manufacture such quantity of the Product or its equivalent that Impax is
unable to produce or, alternatively, Schering may enter into a supply agreement with a Third Party
to manufacture such quantity of the Product or its equivalent that Impax is unable to provide
(taking into account minimum batch sizes and pricing efficiencies of such supplier), upon such
terms and conditions as Schering shall determine in its sole discretion, whereupon Schering’s
purchase obligation under Article IV hereof shall be adjusted accordingly. If the Cure Price for
the Supply Failure is in excess of the Price, Schering shall invoice Impax for an amount equal to
the excess of the Cure Price over the Price and provide reasonable documentation evidencing the
Cure Price to Impax with such invoice. Impax shall pay such invoice within 30
days and such payment obligation shall constitute Impax’s sole and exclusive liability for
claims under this Section 5.4.

          (b) In the event that any Supply Failure shall be caused by a Force Majeure, Schering or an
Affiliate of Schering may (but shall not be obligated to) Manufacture the Product or,
alternatively, Schering may enter into a supply agreement with a Third Party to purchase such
quantity of Product or its equivalent that Impax is unable to produce, upon such terms and
conditions as Schering shall determine in its sole discretion, whereupon Schering’s purchase
obligation under Article IV hereof shall be adjusted accordingly and Impax shall not be required to
pay the Cure Price.

          (c) In the event of a Supply Failure under Section 5.4 (a) or (b) above, Impax shall exercise
Commercially Reasonable Efforts to resume production as quickly as possible and shall notify
Schering in writing upon resumption of production, whereupon it shall supply Schering with Product
with such modified requirements for the Product as Schering may have for the remaining term of this
Agreement.

 

 

          (d) The failure by Impax on more than two occasions during the Initial Term or on more than
two occasions during any renewal period of this Agreement or any period subsequent to such
failures to fill in a timely manner at least 75% of any delivery specified on a purchase order
placed by Schering pursuant to Article IV of this Agreement shall, subject to the terms of Section
16.2, be a material breach of this Agreement.

     5.5 Rejection. If Schering claims that any shipment of Product did not, at the time of
delivery to the carrier designated by Schering, meet the warranties in Section 12.2(b), (c), (d),
(e)(ii), e(v) or (f) or that Impax did not comply with the covenants in Section 12.1, Schering
shall notify Impax. If Impax agrees with Schering’s claim, Impax at its option shall either
promptly replace such Product or reimburse Schering for any payment Schering may have made to Impax
for such Product and for any out-of-pocket expense Schering may have incurred with respect thereto
prior to Schering’s discovery of the defect, including without limitation shipping, insurance,
taxes, and if applicable, packaging costs. If Schering and Impax are unable to agree as to whether
such Product met the warranties or whether Impax complied with the covenants, the parties shall
cooperate to have the Product in dispute analyzed by an independent Third Party testing laboratory
of recognized repute jointly selected by Schering and Impax. If the Product is determined by such
Third Party to meet the Product Specifications, then Schering shall bear the cost of the
independent laboratory testing and pay for the Product in accordance with this Agreement. If the
Product is determined not to have met the Product Specifications at time of delivery, then Impax
shall bear the cost of the independent laboratory testing, and Impax shall, at Schering’s election,
either replace the rejected Product as soon as possible but no later than within sixty (60) days
after the date of such determination, at no cost to Schering, or refund or credit, as designated by
Schering, the price paid for such Product plus any applicable delivery charge, within sixty (60)
days after written notice from Schering. Such laboratory costs, refund,
credit or replacement shall constitute Impax’s sole and exclusive liability for claims under this
Section 5.5.

ARTICLE VI
PAYMENT

     6.1 Price. The Price to be paid by Schering to Impax for the Product during the Initial
Term shall be as set forth on Exhibit 1.29 hereto, and shall be made in United States dollars
within thirty (30) days from date of receipt of invoice therefor for Product received by Schering.
After the Initial Term, the Price to be paid by Schering to Impax for the Product may be increased
for any increase in the United States Consumer Price Index for material, labor and overhead costs
during the immediate preceding year (excluding the fixed costs set forth in Exhibit 1.29), but in
no event shall such cost increase by more than a total of three percent (3%) for such year over the
Price at the end of the immediate preceding year.

     6.2 Taxes. Impax and Schering agree to
cooperate in order to minimize, in the manner permitted under applicable tax and customs laws and
regulations, the taxes (including value-added taxes) and duties associated with the importation
and/or exportation of the Active Pharmaceutical Ingredient and the Product, as the case may
be.

ARTICLE VII
APPROVAL SUPPORT; REGULATORY MATTERS

     7.1 Approval Support. Impax shall produce stability batches and validation batches,

 

 

engage
in various development activities and perform various tests as necessary for receipt of the Health
Registrations in the Territory, including without limitation, being prepared for the pre-approval
inspections by the Regulatory Authorities and performing the other activities set forth in Exhibit
7.1 hereto.

     7.2 Filing and Maintenance of the Health Registrations. Impax shall be
responsible for the preparation, filing and maintenance of the ANDA for the Product, including
without limitation the CMC sections and shall promptly undertake to qualify bulk supply of Product
in drums. In the event Impax subsequently modifies any relevant Health Registration (or the CMC)
for which it is responsible, it shall promptly notify Schering and provide it with copies of such
Health Registration (or CMC) supplements or amendments.

     7.3 Specifications Amendments. Except to the extent specifically required by relevant
Health Authorities, Impax shall not modify the Product Specifications without Schering’s prior
written approval, such approval not to be unreasonably withheld.

     7.4 Impax Approvals. Except as otherwise specifically set forth herein, Impax shall be
responsible for obtaining and maintaining all approvals from the Regulatory Authorities and any
other governmental authorities required in connection with the performance of its obligations
hereunder.

     7.5 Complaints As soon as practical after the Effective Date (and in any event within
one hundred twenty (120) days), Impax and Schering shall negotiate in good faith and agree upon
mutually acceptable guidelines and procedures for investigating, responding to and reporting
product complaints. Notwithstanding any provisions of Section 7.5 and 7.6, Impax is not relieved
of any of its responsibilities as the ANDA holder of the Product. Accordingly, Impax shall
perform all of its obligations in compliance with all applicable laws, rules and regulations,
including without limitation, FDA regulations.

     7.6 Adverse Events. As soon as practical after the Effective Date (and in any event
within one hundred twenty (120) days), Impax and Schering shall negotiate in good faith and agree
upon mutually acceptable guidelines and procedures for adverse drug event information exchange and
reporting.

ARTICLE VIII

QUALITY CONTROL AND REGULATORY COMPLIANCE

     8.1 Facility Compliance and Related Matters. Impax shall maintain the Approved
Facility and shall conduct all Manufacturing in compliance with all applicable laws, rules and
regulations, including cGMPs, and the Impax Know-How at all times during the term of this
Agreement. Impax shall be responsible for all costs and expenses related to the compliance of the
Approved Facility with such laws, rules and regulations and with the Impax Know-How. Impax agrees
to Manufacture the Product at the Approved Facility, and not to change the location thereof without
Schering’s prior written consent.

     8.2 Quality Control Program. Impax shall maintain a quality control program consistent
with cGMPs, as required by the applicable Regulatory Authorities in the Territory. Impax shall,
within thirty (30) days of the Effective Date, provide Schering with a written summary description
of such program establishing that it has met such cGMPs, which may be

 

 

amended or supplemented from
time to time; provided that Impax gives Schering prompt written notice of such amendments or
supplements.

     Impax shall have sole responsibility for quality control testing of each batch of Product
supplied to Schering hereunder to ensure that such Product meets the Product Specifications. Impax
shall retain records of all such testing, copies of which shall be provided to Schering upon
written request. Impax shall provide Schering with a certificate of analysis for each batch of
Product. Schering shall have the right to test Product to verify compliance with the applicable
Product Specifications, at its expense.

     8.3 Approval for Third Party Manufacturing. Impax agrees not to contract with any
Third Party to conduct part or all of the Manufacturing of the Product without the prior written
consent of Schering, which consent can be withdrawn at any time. Impax further agrees not to
contract with any Third Party, other than those listed on its ANDA, to conduct part or all of the
testing of the Product without the prior written consent of Schering, such consent not to be
unreasonably withheld, but which consent can be withdrawn upon at least six (6) months prior
notice.

     8.4 Retention of Samples. Impax shall retain a sufficient quantity of each batch of
Product to perform at least two full sets of quality control tests (which shall be in addition to
the quality control testing performed by Impax prior to delivery). Impax shall maintain samples of
each batch in a suitable environmentally controlled storage facility until at least the first
anniversary of the end of the approved shelf life of all Product from such batch, or such longer
period as may be required under applicable law, regulation or rule. All such samples shall be
available for inspection and testing by Schering or a Third Party chosen by Schering at its sole
discretion, including but not limited to any Affiliate, upon reasonable notice.

     8.5 Batch
Failure. Impax agrees to notify Schering within thirty-six (36) hours of discovery after any
batch failure which could result in Impax’s inability to meet Schering’s requested delivery dates,
or of learning of any failure of any batch of Product to meet standards set forth in the Impax
Know-How. Impax shall notify Schering within thirty-six (36) hours after any failure of a released
batch during stability testing. Impax shall complete out-of-specification investigations within
thirty (30) calendar days from date of discovery.

     8.6 Notification of Regulatory
Inspections. Impax agrees to notify Schering within thirty-six (36) hours after the initiation
of any inquiries, notifications, or inspection activity by any Regulatory Authority in regard to
the Product or the Approved Facility. In furtherance and not in limitation of the foregoing, Impax
shall notify Schering prior to the commencement of any inspection activity by any Regulatory
Authority regarding the Product or any general cGMP inspection, unless such inspection activity is
an unannounced inspection. Further, Impax shall provide a reasonable description to Schering of
any such governmental inquiries, notifications or inspections promptly (but in no event later than
two (2) calendar days) after such visit or inquiry. Impax shall furnish to Schering, (a) within
two (2) days after receipt, any report or correspondence issued by the Regulatory Authority in
connection with such visit or inquiry, including but not limited to, any FDA Form 483,
Establishment Inspection Report, or warning letter, or other regulatory communications and (b)
copies of any and all responses or explanations to any Regulatory Authority relating to items set
forth above, in each case purged only of trade secrets of Impax that are unrelated to its
obligations under this Agreement and are unrelated to the Product, prior to the submission of

 

 

such responses or explanations to any Regulatory Authority by Impax.

     8.7 Inspection by Schering.
Schering shall have the right, during normal business hours (and after normal business hours if
reasonably requested and in connection with a production run commenced during the normal business
hours) and with reasonable advance notice, to visit the Approved Facility for the purpose of
observing the Manufacturing, packaging, testing, and storage of the Product, and to inspect for
compliance to cGMPs and other applicable regulatory requirements. Impax’s quality assurance
department shall cooperate with Schering, as necessary and useful, in any inspection conducted
pursuant to this Section 8.7, and resolve any open observations to Schering’s satisfaction.
Further, Impax shall maintain records of its
involvement with any inspection in accordance with its customary business practices, as long as
such practices satisfy the recordkeeping requirements set forth in Section 15.2 hereof.

     8.8 Environmental and Other Laws and Regulations. In carrying out its obligations under this
Agreement, Impax shall have sole responsibility for compliance with all applicable Laws, including
without limitation environmental and health and safety laws, as amended from time to time. Impax
shall immediately notify Schering in writing of any event, including the receipt of any notice,
warning, citation, finding, report or service of process or the occurrence of any release, spill,
upset, or discharge of hazardous wastes or substances, relating to the Manufacture of the Product
that may give rise to liability on the part of Impax under the Laws or this Agreement. Schering
reserves the right to conduct an environmental inspection of Impax’s facility, during normal
business hours and with reasonable advance notice, for the purpose of determining compliance with
this Section 8.8. Schering shall share the results of any such environmental inspection with
Impax. Such inspection, if any, shall not relieve Impax of its sole obligation to comply with the
Laws and does not constitute a waiver of any right otherwise available to Schering.

ARTICLE IX
PRODUCT RECALL

     9.1 Notification and Recall. In the event that any Regulatory Authority issues or requests
a recall or takes similar action in connection with the Product, or in the event either party
hereto determines an event, incident or circumstance has occurred that may result in the need for a
recall or market withdrawal, the party notified of or determining the need for such recall or
similar action shall, within twenty-four (24) hours, advise the other party thereof by telephone or
facsimile. Following notification of a recall, within forty-eight (48) hours, the parties shall
discuss whether or not to conduct a recall, and if so, the timing of the recall, the breadth,
extent and level of customer to which the recall shall reach, the strategies and notifications to
be used, and other related issues. In the event that the parties cannot agree on any such
decision, the issue shall be resolved by Schering.

     9.2 Recall Expenses. Impax shall bear
the expenses of any recall resulting from a breach of its obligations hereunder. Such expenses of
recall shall include, without limitation and without duplication, the expenses of notification and
destruction or return of the recalled Product, the sum paid by Schering to Impax for the
Manufacture of the recalled Products, Schering’s costs relating to the testing, packaging,
shipping, and retail trade related costs of the recalled Products and the cost to Schering for the
Active Pharmaceutical Ingredient and other Raw Materials or Packaging Components supplied by
Schering and used in the Manufacture of the recalled Products and not paid for by Impax, and any
Losses caused by, arising out of, or resulting from such recall. The rights of Schering under this
Section 9.2 shall be Schering’s sole remedy under this Agreement or at law for such
recall.

 

 

ARTICLE X

INTELLECTUAL PROPERTY RIGHTS

     10.1
Intellectual Property Rights. 

          (a) Schering shall own all right, title to and
interest in the Intellectual Property of Schering or derivatives thereof developed by or on behalf
of Schering in performance of this Agreement. In no case, except as provided explicitly herein,
whether during the term of this Agreement or upon expiration or any termination thereof, shall
Impax or any Third Party be deemed to have or be entitled to any right or license to any
Intellectual Property of Schering or any Intellectual Property controlled or licensed by Schering.
Impax shall provide Schering with reasonable assistance in executing and filing any documents
necessary to evidence Schering’s ownership of its Intellectual Property, including, without
limitation, executing any assignments or providing assistance with filing for and maintaining
patents with respect to the Intellectual Property of Schering.

          (b) Impax shall own all right, title to and interest in the Intellectual Property of Impax or
derivatives thereof developed by or on behalf of Impax in performance of this Agreement. In no
case, except as provided explicitly herein, whether during the term of this Agreement or upon
expiration or any termination thereof, shall Schering or any Third Party be deemed to have or be
entitled to any right or license to any Intellectual Property of Impax or any Intellectual Property
controlled or licensed by Impax. Schering shall provide Impax with reasonable assistance in
executing and filing any documents necessary to evidence Impax’s ownership of its Intellectual
Property, including, without limitation, executing any assignments or providing assistance with
filing for and maintaining patents with respect to the Intellectual Property of Impax.

          (c) During the term of this Agreement, in the event that Impax develops, discovers or creates
any Inventions relating to the Product or the Manufacture and use thereof, such Inventions shall be
the sole property of Impax.

     10.2. Licenses. Schering shall grant to Impax, upon the earlier of (a) the date
Schering’s existing proprietary D-12 formulation is approved for OTC sale, or (b) such other date
as otherwise agreed to by the parties, a limited non-exclusive, non-transferable license and right
to use in the Territory, without the right to sub-license, the Schering Intellectual Property
solely to the extent required for Impax to perform its obligations hereunder and only for the
benefit of Schering. Subsequent to such grant, Schering shall in good faith cooperate with Impax
to seek removal of any statutory stay or prohibition on approval then in effect by the Regulatory
Authorities of ANDA 76-050 so that Impax may manufacture and supply Product for Schering; provided,
however, that nothing in this Agreement shall be construed to obligate Schering to settle, dismiss,
or take any other particular actions in Civil Action No. 01-0279 currently pending in the United
States Distinct Court for the District of New Jersey. Notwithstanding any other provision of this
Agreement, nothing in this Agreement shall constitute either an express or implied grant to Impax
of any rights to Schering Intellectual Property for use or manufacture for any other party other
than Schering.

 

 

     10.3. Trademarks and Trade Names. Schering and Impax hereby acknowledge that neither party
has, nor shall either party acquire by reason of this Agreement, any interest or rights of use in
any of the other party’s trademarks, trade names, trade dress, designs or logos unless otherwise
expressly agreed in writing between the parties hereto.

ARTICLE XI

TERM AND TERMINATION

     11.1 Term. This Agreement shall terminate upon the expiration of the Initial Term,
unless sooner terminated by one of the parties in accordance with this Article XI or unless renewed
pursuant to Section 11.5 below.

     11.2 Termination by Schering. (a) Schering shall have the
right to terminate this Agreement upon ninety (90) days’ prior notice to Impax if:

     (i) Impax is
subject to any Regulatory Authority warning letter or sanction, which is general in nature or
relates specifically to the Product, and which is not conclusively resolved between Impax and the
Regulatory Authority within one hundred eighty (180) days of issue; provided, however, that Impax
must diligently pursue resolution of such warning letter or sanction during such period;

     (ii) there is a change in control of Impax. For purposes of this provision, a “change in
control” shall mean the acquisition of direct or indirect ownership of over fifty percent (50%) of
the outstanding voting securities of Impax, or actual control over the management, business and
affairs of Impax, by a non-Affiliate thereof; or

     (iii) Impax files a petition in bankruptcy, or enters into an arrangement with its creditors,
or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for
the benefit of creditors, or suffers or permits the entry of an order adjudicating it to be
bankrupt or insolvent. In the event this Agreement is terminated under this Section 11.2(iii), all
rights and licenses granted pursuant to Section 10.2 of this Agreement by Impax to Schering are,
and shall otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code,
licenses of rights to “intellectual property” as defined under Section 101(52) of the Bankruptcy
Code. The parties agree that Schering, as a licensee of such rights under this Agreement, shall
retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The
parties further agree that, in the event of the commencement of a bankruptcy proceeding by or
against Impax under the Bankruptcy Code, Schering shall be entitled to a complete duplicate of (or
complete access to, as appropriate) any such intellectual property and all embodiments of such
intellectual property upon written request therefor by Schering. Such intellectual property and
all embodiments thereof shall be promptly delivered to Schering (i) upon any such commencement of a
bankruptcy proceeding upon written request therefor by Schering, unless Impax elects to
continue to perform all of its obligations under this Agreement or (ii) if not delivered under
(i) above, upon the rejection of this Agreement by or on behalf of Impax upon written request
therefor by Schering.

          (b) Either party shall have the right to terminate this Agreement on or after January 1, 2003,
if Impax has not yet received tentative ANDA approval by January 1, 2003.

     11.3 Termination for Material Default. (a) Except for a breach under Section 11.3(b)
hereof, upon default by a party in the performance of any material obligation under this

 

 

Agreement,
the non-defaulting party shall give notice in writing to the party in default and the defaulting
party shall have sixty (60) days thereafter to cure the default. The defaulting party shall,
immediately upon receipt of such notice, take diligent steps to cure such default. If the
defaulting party does not cure or institute measures to substantially cure such default within
thirty ( 30) days and diligently complete the cure within an additional thirty (30) days (unless
such thirty (30) day period is not a sufficient period of time to cure such default, in which event
the defaulting party shall have up to an additional 30 days to cure such default), the
non-defaulting party may terminate this Agreement by providing written notice of intent to
terminate which shall take effect ten (10) days following the receipt by the defaulting party of
such notice.

          (b) Impax recognizes that, in the absence of this Agreement, it would be barred by
applicable laws and regulations from making, using, selling, offering to sell or importing within
the United States the loratadine product defined by ANDA 76-050, prior to the earlier of July 25,
2003 or a decision by the New Jersey District Court in Civil Action No. 01-0279 holding that Claims
1 and 3 of U.S. Patent No. 4,659,716 are invalid, unenforceable or not infringed by such product.
Accordingly, it shall constitute a material breach of this Agreement in the event that Impax, prior
to the earlier of July 25, 2003 or a decision by the New Jersey District Court in Civil Action No.
01-0279 holding that Claims 1 and 3 of U.S. Patent No. 4,659,716 are invalid, unenforceable or not
infringed by such product, undertakes to, or actually, , sells or distributes within the United
States the loratadine product defined by ANDA 76-050 for any purpose other than supplying Schering
under the terms of this Agreement (hereinafter “Prohibited Actions”). Impax stipulates and agrees
that such Prohibited Actions and material breach of this Agreement would: (1) not be subject to
the provisions of Section 11.3(a) of this Agreement; (2) cause Schering immediate, irreparable harm
for which monetary damages would not be adequate compensation; and (3) entitle Schering to obtain a
temporary restraining order, and injunction enjoining such Prohibited Actions.

     11.4 Effect of Termination. Expiration or termination of this Agreement shall not relieve
the parties of any obligation accruing prior to such expiration or termination, and the provisions
of Sections 7.5, 7.6, 8.4, 8.6, 11.4, 11.6 and 16.8 hereof and Articles IX, X, XII, XIII, XIV and
XV hereof shall survive the expiration or termination of this Agreement. Any expiration or early
termination of this Agreement shall be without prejudice to the rights of either party against the
other accrued or accruing under this Agreement prior to termination.

     11.5 Option to Renew.
So long as Schering is not in breach of this Agreement,
the term of this Agreement may be extended for an additional term of two (2) years at Schering’s
option, in accordance with the same terms of this Agreement; provided however that the Active
Ingredient Prices for the renewal period shall be as set forth on Exhibit 3.1 hereof. In the event
that Schering, in its sole discretion, wishes to extend the term of this Agreement it shall provide
written notice to that effect to Impax at least one hundred and eighty (180) days prior to the end
of the Initial Term. Impax shall respond in writing to such notice within thirty (30) days,
acknowledging the extension of the term of the Agreement. If Schering elects not to extend the
Agreement, then the Agreement shall expire at the end of the Initial Term.

     11.6 Right to Manufacture. Notwithstanding any other provisions of this Agreement, in
the event that Impax has an uncured material breach in accordance with Section 11.3 hereof,

 

 

Schering shall have the right to manufacture the Product or have the Product manufactured by a
Third Party in accordance with the Agreement, with no further payment obligations to Impax for any
amounts relating to such manufactured Product.

ARTICLE XII

COVENANTS; REPRESENTATIONS AND WARRANTIES

     12.1 Impax’s Covenants. Impax covenants that,

     (a) at the time of delivery of the Product to the designated carrier pursuant to Section 5.2
hereof, the Product shall:

               (i) have been Manufactured, tested, stored and shipped and had stability oversight conducted
in accordance with applicable cGMPs and all other applicable laws, rules, regulations or
requirements of Regulatory Authorities in the Territory;

               (ii) have been Manufactured in accordance with the Impax Know-How, including without
limitation the Product Specifications and the CMC;

               (iii) not be adulterated or misbranded under the FDCA or the Laws;

               (iv) have been Manufactured no more than two (2) months (if shipment in bulk) or three (3)
months (if shipment in bottles)prior to delivery to the designated carrier pursuant to Section 5.2
hereof; and

               (v) be in good, usable and merchantable condition and fit for its intended purpose.

          (b) it will have good and marketable title, free and clear of any liability, pledge, lien,
restriction, claim, charge, security interest or other encumbrance, to all Product delivered to the
designated carrier pursuant to Section 5.2 hereof;

          (c) it will not use in any capacity, in connection with the services to be performed under
this Agreement, any person who has been debarred pursuant to Section 306 of the FDCA (codified at
21 U.S.C. §335a), or who is the subject of a conviction described in such section;

          (d) it will inform Schering in writing immediately if it or any person who is performing
services hereunder is debarred or is the subject of a conviction described in Section 306 of the
FDCA, or if any action, suit, claim, investigation, or legal or administrative proceeding is
pending or, to the best of Impax’s knowledge, is threatened, relating to the debarment or
conviction of Impax or any person performing services hereunder; and

 

 

          (e) it will promptly notify Schering in writing of any material adverse change in the business
of Impax which could affect Impax’s ability to perform its obligations under this Agreement.

          (f) it will not , sell or distribute within the United States, loratadine for the purpose of
commercially marketing a loratadine product under ANDA 76-050, outside of supplying Schering under
the license granted under this agreement (hereinafter “prohibited actions”) prior to the earlier of
July 25, 2003 or a decision by the New Jersey District Court in Civil Action No. 01-0279 holding
that claims 1 and 3 of U.S. Patent No. 4,659,716 are invalid, unenforceable or not infringed by the
product defined by ANDA 76-050.

     12.2 Impax’s Representations and Warranties. Impax represents and warrants to Schering
that,

          (a) it has the financial resources, appropriate skills, personnel, equipment, permits, and
approvals necessary or useful to perform its obligations under this Agreement in compliance with
the Laws;

          (b) it owns, or is licensed with the right to sublicense, all Intellectual Property rights
(including without limitation the Impax Know-How) necessary or useful to Manufacture the Product;

          (c) to the best of its knowledge as of the Effective Date, the Impax Intellectual Property
does not infringe the Intellectual Property rights of any Third Party;

          (d) it is not aware of any Third Party infringement of its Intellectual Property rights;

          (e) no material adverse change has occurred within the past six (6) months, with respect to
Impax and its operations including without limitation material changes in or to its;

               (i) insurance coverage;

               (ii) threatened or pending legal claims affecting the Product;

               (iii) labor pool;

               (iv) suppliers;

               (v) quality assurance systems; or

               (vi) key personnel;

          (f) it has good and marketable title to and/or right to use, the equipment and other assets
useful or necessary to Manufacture the Product at the Approved Facilities;

 

 

          (g) it has adequate capacity to meet Schering’s initial forecast as set forth on Exhibit 3.3,
its own requirements for Product and the requirements of any other purchasers of Product that Impax
chooses to sell Product.

     12.3 Representations and Warranties of Schering. Schering hereby further represents
and warrants to Impax that:

          (a) Schering has not and will not, enter into any agreement or any other transaction with any
third party or Affiliate that impedes Schering’s obligations under this Agreement; provided,
however, that Impax acknowledges that Schering is in the business of developing, manufacturing and
selling pharmaceutical products and nothing in this Agreement shall be construed as restricting
such business.

          (b) In the event that Schering and/or its Affiliates shall manufacture a product pursuant to
Section 5.4(a), all such product shall (a) meet the applicable Specifications at the time of
shipment, (b) meet all regulatory requirements of any relevant Regulatory Authority in the
Territory, (c) be manufactured, packaged, tested, stored and shipped in accordance with Regulatory
Approval and all Laws, (d) not be adulterated or misbranded under the FDCA or relevant laws and
regulations and (e) be produced, packaged and tested and stored in environmentally controlled
facilities that have been approved by the applicable Regulatory Authority to the extent required by
Law.

          (c) In the event and to the extent that Schering and/or its Affiliates shall manufacture a
product pursuant to Section 5.4(a), Schering’s and/or its Affiliates’ manufacturing facilities for
such product shall conform in all respects to Laws governing such facilities.

          (d) Neither Schering nor any of its Affiliates shall have been debarred or is subject to
debarment and will not use in any capacity, in connection with the services to be performed under
this Agreement, any Person who has been debarred pursuant to Section 306 of the FDCA or is the
subject of a conviction described in such section, and

          (e) All Product which Schering shall package, test, store, ship or market under this
Agreement shall have been marketed and stored in accordance with Regulatory Approval and all Laws.

     12.4. Impax’s and Schering’s Representations and Warranties. Each of Impax
and Schering hereby represents and warrants to the other as
follows:

     (a) it is a corporation duly
organized and validly existing under the laws of the state or other jurisdiction in which it is
incorporated;

     (b) the execution, delivery and performance of this Agreement by such party has been duly
authorized by all requisite corporate action;

 

 

     (c) it has the power and authority to execute and deliver this Agreement and to perform its
obligations hereunder;

     (d) the execution, delivery and performance by such party of this Agreement and its compliance
with the terms hereof does not and will not conflict with or result in a breach of any term of, or
constitute a default under (i) any agreement or instrument binding or affecting it or its property;
(ii) its charter documents or bylaws; or (iii) any order, writ, injunction or decree of any court
or governmental authority entered against it or by which any of its property is bound;

     (e) it has obtained any consent, approval or authorization of, or notice, declaration, filing
or registration with, any governmental or Regulatory Authority required for the execution, delivery
and performance of this Agreement by such party, and the execution, delivery and performance of
this Agreement will not violate any law, rule or regulation applicable to such party;

     (f) this Agreement has been duly executed and delivered and constitutes such party’s legal,
valid and binding obligation enforceable against it in accordance with its terms subject, as to
enforcement, to bankruptcy, insolvency, reorganization and other laws of general applicability
relating to or affecting creditors’ rights and to the availability of particular remedies under
general equity principles; and

     (g) it shall comply with all applicable laws, rules and regulations relating to its
performance under this Agreement.

     12.5. EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
WARRANTY OF ANY KIND, EXPRESS OR IMPLIED.

ARTICLE XIII

INDEMNIFICATION AND INSURANCE

     13.1 Impax’s Indemnification Obligation. Impax shall indemnify, defend and hold
Schering, its Affiliates and each of its and their respective employees, officers, directors and
agents harmless from and against all Losses caused by, arising out of, or resulting from: (a)
Impax’s breach of this Agreement; or (b) any infringement of Third Party patents by Impax’s use of
its Intellectual Property for the Manufacture of the Product or by Schering’s use of Impax’s
Intellectual Property as licensed hereunder, in each case except to the extent caused by the
negligence or intentional misconduct of Schering.

     13.2 Schering’s Indemnification
Obligation. Schering shall indemnify, defend and hold Impax, its Affiliates and each of its
and their respective employees, officers, directors and agents harmless from and against all Losses
caused by, arising out of, or resulting from: (a) Schering’s breach of this Agreement; or (b) the
marketing, packaging, storage, shipment and sale of Product in the Territory by Schering, in each
case except to the extent caused by the negligence or intentional misconduct of Impax.

     13.3 Conditions to Indemnification. (a) The indemnified party shall give the indemnifying

 

 

party prompt written notice of (i) the institution of any suit against the indemnified party for
which it may seek indemnification under this Article XIII and (ii) any claims, including any claims
asserted or made by any Regulatory Authority having jurisdiction, against the indemnified party for
which it may seek indemnification under this Article XIII. The failure to give such notice shall
not relieve the indemnifying party from any liability that it may have to the indemnified party
under this Article XIII except to the extent that the indemnifying party’s ability to defend such
suit or claim is materially prejudiced by the failure to give such notice. The indemnifying party
shall be entitled to participate in the defense of such suit or claim and to assume control of such
defense; provided, however, that if it assumes such defense:

               (i) the indemnified party shall be entitled to participate in the defense of such claim and to
employ counsel at its own expense to assist in the handling of such claim;

               (ii) the indemnifying party shall obtain the prior written approval of the indemnified
party before entering into any settlement of such claim or ceasing to defend against such
claim, if, pursuant to or as a result of such settlement or cessation, injunctive or other
equitable relief would be imposed against the indemnified party; and

               (iii) the indemnifying party shall not consent to the entry of any judgment or enter
into any settlement that does not include as an unconditional term thereof the giving by the
claimant or plaintiff to each indemnified party of a release from liability in respect of
such claim.

Notwithstanding the foregoing, the indemnified party shall be entitled to have sole control at its
own expense over the defense or settlement of any suit or claim to the extent the suit or claim
could materially adversely affect the business, operations, assets, condition or prospects of the
indemnified party and the indemnifying party shall be entitled to participate at its own expense in
such defense or settlement.

     (b) After written notice by the indemnifying party to the indemnified party of its election to
assume control of the defense of any such action, the indemnifying party shall not be liable to
such indemnified party hereunder for any legal fees and expenses subsequently incurred by such
indemnified party in connection with the defense thereof. If the indemnifying party does not
assume control of the defense of such claims as provided in this Section 13.3(b), the indemnified
party shall have the right to defend such claim in such manner as it may deem appropriate at the
cost and expense of the indemnifying party, and the indemnifying party shall promptly reimburse the
indemnified party therefor in accordance with this Section 13.3(b). The reimbursement of fees,
costs and expenses required by this Section 13.3(b) shall be made by periodic payments during the
course of the investigation or defense, as and when bills are received or expenses incurred. The
indemnified party shall provide to the indemnifying party, as promptly as practicable after any
claim for indemnification hereunder, such information and documentation as may be reasonably
requested by the indemnifying party to support and verify the claim asserted, so long as such
disclosure would not violate the attorney-client privilege of the indemnified party.

 

 

     13.4 Insurance. Impax represents and warrants that during the term of this Agreement,
it shall maintain the types and amounts of insurance set forth
below:

     (a) general liability
insurance, including contractual liability coverage of all of Impax’s obligations under this
Agreement and products liability/completed operations coverage with a minimum limit of ten million
dollars ($10,000,000).

     (b) Such insurance shall be evidenced by a certificate of insurance which shall provide that Schering
shall receive thirty (30) days’ prior written notice of cancellation or material change of such
policy. 

     13.5 Exclusion. Notwithstanding any provision of this Agreement to the contrary, in no
event shall either party be liable to the other under this Agreement for any incidental,
consequential, punitive or special damages, including without limitation loss of profit or
revenues; provided, however, such limitation shall not apply to lawsuits, claims,
actions or proceedings instituted by a Third Party against a party hereto, which are caused
(directly or indirectly) by facts or circumstances constituting a breach of this Agreement by the
other party.

ARTICLE XIV

CONFIDENTIALITY

     14.1 Confidentiality. Impax and Schering acknowledge that each party considers its
Proprietary Information to be of significant value and that such information shall be maintained as
confidential. Each party shall use Proprietary Information disclosed to it by or on behalf of the
other party only for the purposes contemplated by this Agreement and shall not disclose such
Proprietary Information to any Third Party without the prior written consent of the disclosing
party. The foregoing obligations shall survive the expiration or termination of this Agreement for
a period of ten (10) years. These obligations shall not apply to Proprietary Information that:

     (a) is known by the receiving party at the time of its receipt, and not through a prior disclosure by
the disclosing party, as documented by business records;

     (b) is at the time of disclosure, or thereafter becomes, published or otherwise part of the
public domain without breach of this Agreement by the receiving party;

     (c) is subsequently disclosed to the receiving party by a Third Party who has the right to
make such disclosure;

     (d) is independently developed by the receiving party without the aid, application of
Proprietary Information or other information received from the disclosing party and such
independent development is properly documented by the receiving party;

     (e) is disclosed to governmental or other regulatory agencies (including without limitation
Institutional Review Boards) in order to gain approval to conduct clinical trials or to market
Product, provided that such disclosure is permitted only to the extent reasonably necessary to
obtain such authorizations;

     (f) is required to be disclosed by law, regulation, rule, act or order of a governmental
authority or agency, provided that the receiving party promptly notifies the other party in order
to provide an opportunity to seek a protective order or other similar order with respect to such

 

 

Proprietary Information and thereafter discloses only the minimum information required to be
disclosed in order to comply, whether or not a protective order or other similar order is obtained
by the other party.

Nothing herein shall be interpreted to prohibit Schering from publishing the results of its studies
in accordance with industry practices. Each party shall have the right to disclose the other
party’s Proprietary Information to its Affiliates in connection with the research and development,
manufacturing and/or marketing of Product in accordance with the terms of this Agreement, provided
that each party shall be responsible for ensuring that its Affiliates comply with the
confidentiality and use restrictions set forth herein. The parties acknowledge that the terms and
provisions of the Secrecy Agreement dated January 7, 2002, which the parties entered into are
incorporated herein by reference.

     14.2 No Publicity. A party may not use the name of the other party in any publicity or
advertising and may not issue a press release or otherwise publicize or disclose the existence of
this Agreement, any information related to this Agreement or the terms or conditions hereof,
without the prior written consent of the other party. Nothing in the foregoing, however, shall
prohibit a party from making such disclosures as are necessary to comply with applicable federal or
state securities laws or any rule or regulation of any nationally recognized securities exchange;
provided, however, that the party required to make such disclosure shall use good
faith efforts to consult with the other party prior to such disclosure and, where applicable, shall
request confidential treatment to the extent available.

ARTICLE XV

RECORDS

     15.1 Financial and Other Records. Impax shall maintain records with respect to the
performance of its obligations under this Agreement, including without limitation its costs
incurred in connection therewith. Specifically, but without limitation, Impax shall maintain all
records reasonably necessary to support financial accounting entries necessary to support changes
in Price pursuant to Section 6.1 hereof . All such records shall be available for inspection,
audit and copying by Schering and its representatives and agents, including Schering’s auditors,
upon reasonable request during normal business hours. All such records shall be maintained until
at least two (2) years after the date of a change in Price pursuant to Section 6.1 hereof, or such
longer period as may be required by the Laws.

     15.2 Product Records. Impax shall maintain
all records necessary to comply with the Laws and in accordance with the Health Regulations. In
addition, Impax shall prepare and adhere to batch process documentation consistent with the Impax
Know-How, and in accordance with its normal procedures, including without limitation quality
control records and all raw data relating to each batch processed. Specifically, but without
limitation, Impax shall maintain complete and accurate records reasonably necessary to support
cGMPs and other applicable regulatory requirements in the Territory, including without limitation
quality control records. All such records shall be available for inspection, and audit by
Schering (at its expense) and its representatives and agents, including Schering’s auditors upon
reasonable request during normal business hours. All such records shall be maintained for the
longest period as may be required by the Laws; provided, however, that all records
relating to the Manufacture, testing, stability oversight and quality control of each batch of the
Product shall be retained at least until the third

 

 

anniversary of the end of the approved shelf
life for all Product from such batch. Impax shall provide Schering on a periodic basis, and at
least annually, such information concerning Product, production batches, yields and quality status
as is specified in the Health Registrations (commonly referred to as Annual Product Reviews) and as
may be reasonably requested by Schering from time to time. Prior to destruction of any record,
Impax shall give notice to Schering, which shall have the right to request and retain such record.

     15.3 Financial Information Reporting. Impax shall provide Schering on a quarterly
basis with quarterly financial statements which are made available to the public and prepared in
accordance with GAAP.

ARTICLE XVI

MISCELLANEOUS

     16.1 Assignment. Neither this Agreement nor any or all of the rights and obligations
of a party hereunder shall be assigned, delegated, sold, transferred, sublicensed (except as
otherwise provided herein) or otherwise disposed of, by operation of law or otherwise, to any Third
Party other than an Affiliate of such party, without the prior written consent of the other party,
and any attempted assignment, delegation, sale, transfer, sublicense or other disposition, by
operation of law or otherwise, of this Agreement or of any rights or obligations hereunder contrary
to this Section 16.1 shall be void and without force or effect; provided, however,
Schering may, without such consent, and Impax may with Schering’s consent (which consent shall not
be unreasonably withheld), assign the Agreement and its rights and obligations hereunder in
connection with the transfer or sale of all or substantially all of its assets related to the
division or the subject business, or in the event of its merger or consolidation or change in
control or similar transaction. This Agreement shall be binding upon, and inure to the benefit of,
each party, its Affiliates, and its permitted successors and assigns. Each party shall be
responsible for the compliance by its Affiliates with the terms and conditions of this
Agreement.

     16.2. Force Majeure. Failure of either party hereto to perform its obligations
under this Agreement (except the obligation to make payments when due) shall not subject such party
to any liability to the other party or place it in breach of any term or condition of this
Agreement if such failure is caused by a Force Majeure, provided, however, that the
party affected shall promptly notify the other party of the condition constituting a Force Majeure
and shall exert Commercially Reasonable Efforts to overcome any such causes and to resume
performance of its obligations with all possible speed, and provided, further that nothing
contained herein shall require any party to settle on terms unsatisfactory to such party any
strike, lock-out or other labor difficulty, any investigation or proceeding by any public
authority, or any litigation by any Third Party. If a condition constituting a Force Majeure
exists for more than ninety (90) consecutive days, the parties shall meet to negotiate a mutually
satisfactory solution to the problem, if practicable.

     16.3. Governing Law. This Agreement
shall be governed, interpreted and construed in accordance with the laws of the State of New
Jersey, without giving effect to conflict of law principles.

     16.4. Waiver. Any delay or
failure in enforcing a party’s rights under this Agreement or any waiver as to a particular default
or other matter shall not constitute a waiver of such party’s rights to the future enforcement of
its rights under this Agreement, nor operate to bar the exercise or enforcement thereof at any time
or times thereafter,

 

 

excepting only as to an express written and signed waiver as to a particular
matter for a particular period of time.

     16.5. Independent Relationship. Nothing herein contained shall be deemed to create an
employment, agency, joint venture or partnership relationship between the parties hereto or any of
their agents or employees, or any other legal arrangement that would impose liability upon one
party for the act or failure to act of the other party. Neither party shall have any power to
enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf
of, the other party, or to bind the other party in any respect whatsoever.

     16.6. Export Control. This Agreement is made subject to any restrictions concerning the export of products or
technical information from the United States of America which may be imposed upon or related to
Impax or Schering from time to time by the government of the United States of America.
Furthermore, Schering agrees not to export, directly or indirectly, any technical information
acquired from Impax under this Agreement or any products using such technical information to any
country for which the United States government or any agency thereof at the time of export requires
an export license or other governmental approval, without first obtaining the written consent to do
so from the Department of Commerce or other agency of the United States government as required by
an applicable statute or regulation.

     16.7. Entire Agreement; Amendment. This Agreement,
including the exhibits and schedules hereto, sets forth the complete and final agreement and all
the covenants, promises, agreements, warranties, representations, conditions and understandings
between the parties hereto and supersedes and terminates all prior agreements, writings and
understandings between the parties with respect to the subject matter hereof. The parties agree
that there are no covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the parties other than as are set forth herein and
therein. No subsequent alteration, amendment, change or addition to this Agreement shall be
binding upon the parties unless reduced to writing and signed by an authorized officer of each
party.

     16.8. Notices. Each notice required or permitted to be given or sent under this
Agreement shall be given by facsimile transmission (with confirmation copy by registered
first-class mail) or by registered or overnight courier (return receipt requested), to the parties
at the addresses and facsimile numbers indicated below.

     If to Impax, to:

Impax Laboratories, Inc.

3735 Castor Avenue

Philadelphia, PA 19124

Attention: Barry R. Edwards, Co-Chief Executive Officer

Facsimile No.: 215-289-5932

with copies to:

Sol Genauer, Esq.

Blank, Rome, Comisky & McCauley

                                                            

                                                            

 

 

     If to Schering, to:

Schering Corporation

2000 Galloping Hill Road

Kenilworth, New Jersey 07033

Attention: James Martin, Director of Strategic Sourcing

Facsimile No.: (908) 629-3062

with copies to:

Attention: Law Department, Staff Vice-President, Licensing

Facsimile No.: (908) 298-2739

Any such notice shall be deemed to have been received on the earlier of the date actually received
or the date five (5) days after the same was posted or sent. Either party may change its address
or its facsimile number by giving the other party written notice, delivered in accordance with this
section.

     16.9. Severability. If any provision of this Agreement is declared invalid or
unenforceable by a court having competent jurisdiction, it is mutually agreed that this Agreement
shall continue in effect except for the part declared invalid or unenforceable by order of such
court. The parties shall consult and use diligent efforts to agree upon a valid and enforceable
provision which shall be a reasonable substitute for such invalid or unenforceable provision in
light of the intent of this Agreement.

     16.10. Recording. Each party hereto shall have the
right, at any time, to record, register, or otherwise notify this Agreement with or to appropriate
governmental or regulatory entities in the Territory, and the other party shall provide reasonable
assistance as required in effecting such recording, registration or notification.

     16.11. Counterparts. This Agreement shall become binding when any one or more
counterparts hereof, individually or taken together, have been executed on behalf of each of the
parties hereto. This Agreement may be executed in any number of counterparts, each of which shall
be an original as against any party whose signature appears thereon, but all of which taken
together shall constitute but one and the same instrument.

     16.12 Arbitration. Prior to
submission of any controversy or dispute arising out of or relating to this Agreement (“Dispute”)
to arbitration in accordance with this Section 16.12, the Parties will negotiate in good faith to
resolve such Dispute. If the Parties cannot reach agreement
within ten (10) days of written notice by a Party to the other that a Dispute exists, the
Dispute shall be settled by arbitration before three (3) neutral arbitrators (at least one of which
arbitrators shall have substantial intellectual property experience) in accordance with the then
current rules of the American Arbitration Association. Any such arbitration shall be conducted and
determined in Philadelphia, Pennsylvania. The decision of the arbitrators shall be binding on the
parties. The award rendered by the arbitrators shall be final and judgment may be entered upon it
in any court having jurisdiction thereof. The prevailing party shall be entitled as part of the
award to all

 

 

reasonable fees and expenses incurred in connection with the arbitration, including
the reasonable fees and expenses of the arbitrators and reasonable attorney’s fees. The parties
agree that arbitration proceedings must be instituted within one (1) year after knowledge of the
occurrence of the breach and that the failure to institute arbitration proceedings within such
period shall constitute a waiver of all claims and an absolute bar to institution of any and all
proceedings to arbitrate or adjudicate such claims.

 

 

IN WITNESS WHEREOF, Schering and Impax have caused this Agreement to be executed by their duly
authorized officers as of the day and year first above written.

	 	 	 	 	 	 	 	 	 	 	 
	SCHERING CORPORATION	 	 	 	IMPAX LABORATORIES, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Steven Chellevold
	 	 	 	By:
	 	/s/ Barry R. Edwards	 	 
	 

	 	 
	 	 	 	 	 	 	 	 
	 	 	Name: Steven Chellevold	 	 	 	 	 	Name: Barry R. Edwards	 	 
	 	 	Title: Senior Vice President — Technical Operations	 	 	 	 	 	Title: Co-Chief Executive Officer	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date: June 10, 2002	 	 	 	Date: June 18, 2002

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]